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Table S1. G6PD 202 A- genotype and haemoglobin levels on day 3 after initiation of treatment with Artemether-Lumefantrine (AL) plus placebo or AL 
plus different doses of primaquine 







Absolute change in Hb concentration on day 3 compared to baseline     
G6PD normal mean change, g/dL (sd) -0.71 (0.85) -0.47 (0.97) -0.63 (0.96) -0.46 (1.17) 
G6PD heterozygous  mean change, g/dL (sd) -1.25 (1.13) -0.96 (0.80) -0.66 (1.08) -1.05 (1.09) 
 Comparison G6PD normal,    (se); p-value* -0.45 (0.25); 0.07 -0.36 (0.25); 0.14 -0.02 (0.25); 0.95 -0.48 (0.26); 
0.066 
G6PD hemi-/homozygous mean change, g/dL (sd) -0.65 (0.66) -0.29 (1.05) -0.55 (1.06) -1.12 (0.94) 
 Comparison G6PD normal,    (se) p-value* 0.12 (0.44); 0.78 -0.08 (0.28); 0.78 -0.11 (0.39); 0.78 -0.39 (0.42); 0.35 
Relative change in Hb on day 3 as percentage of baseline concentration     
G6PD normal % change (sd) -6.26 (7.66) -3.64 (8.63) -5.46 (8.56) -3.49 (9.79) 
G6PD heterozygous  % change (sd) -10.75 (10.15) -7.95 (6.80) -5.53 (9.59) -8.37 (8.80) 
 Comparison G6PD normal,    (se); p-value* -3.96 (2.27); 
0.083 




G6PD hemi-/homozygous % change (sd) -4.86 (5.82) -2.45 (10.03) -4.92 (9.75) -9.48 (8.47) 
 Comparison G6PD normal,    (se) p-value* 1.76 (4.02); 0.66 -0.86 (2.60); 0.74 -0.79 (3.60); 0.83 -4.07 (3.63) 0.27 
All primaquine or placebo treatment was administered together with six doses of artemether-lumefantrine (AL); primaquine/placebo was given on day 2 of 
treatment, together with dose 5 of AL. Sd=standard deviation; * p-value compared to G6PD normal individuals, adjusted for baseline Hb concentration.  
  
Table S2. G6PD 202 A- genotype and haemoglobin levels on day 7 after initiation of treatment with Artemether-Lumefantrine (AL) plus placebo or AL 
plus different doses of primaquine 
 







Absolute change in Hb concentration on day 7 compared to 
baseline 
    
G6PD normal mean change, g/dL (sd) -0.41  (0.95) -0.25 (1.22) -0.30 (1.07) -0.11 (1.33) 
G6PD heterozygous  mean change, g/dL (sd) -1.08 (1.14) -0.99  (1.48) -0.07 (0.98) -0.49 (1.40) 
 Comparison G6PD normal,    (se); p-
value* 




mean change, g/dL (sd) -1.10 (1.34) -0.48 (0.76) -0.07 (1.21) -1.02 (0.81) 
 Comparison G6PD normal,    (se) p-
value* 
-0.59 (0.47); 0.21 -0.66 (0.32); 0.043 -0.05 (0.40); 0.91 -0.57 (0.46); 
0.22 
Relative change in Hb on day 7, as percentage of baseline 
concentration 
    
G6PD normal % change (sd) -3.25 (8.60) -1.28 (11.24) -2.16 (9.71) -0.23 (11.34) 
G6PD heterozygous  % change (sd) -9.38 (10.4) -7.79 (12.57) -0.01 (8.56) -3.26 (12.26) 
 Comparison G6PD normal,    (se); p-
value* 




% change (sd) -7.97 (12.40) -4.29 (7.70) -0.05 (11.45) -8.59 (7.28)  
 Comparison G6PD normal,    (se) p-
value* 
-3.91 (4.29); 0.36 -6.71 (3.02); 0.028 -0.33 (3.68); 0.93 -5.66 (4.04); 
0.16 
All primaquine or placebo treatment was administered together with six doses of artemether-lumefantrine (AL); primaquine/placebo was given on day 2 of 
treatment, together with dose 5 of AL. Sd=standard deviation; * p-value compared to G6PD normal individuals, adjusted for baseline Hb concentration.  
 
  
Table S3. G6PD 202 A- genotype and haemoglobin levels on day 10 after initiation of treatment with Artemether-Lumefantrine (AL) plus placebo or AL 
plus different doses of primaquine 
 







Absolute change in Hb on day 10     
G6PD normal mean g/dL (sd) -0.13 (1.14) 0.07 (1.22) -0.16 (1.24) -0.06 (1.21) 
G6PD heterozygous  mean g/dL (sd) -0.87 (0.82) -0.35 (1.46) 0.17 (0.98) 0.01 (1.32) 
 Comparison G6PD normal,    (se); p-value* -0.54 (0.28); 0.06 -0.19 (0.29); 0.52 0.35 (0.27); 0.19 0.02 (0.25); 0.93 
G6PD hemi-/homozygous mean g/dL (sd) -0.80 (1.36) 0.10 (0.99) 0.43 (1.14) -0.68 (0.84) 
 Comparison G6PD normal,    (se) p-value* -0.53 (0.50); 0.29 -0.37 (0.33); 0.26 0.20 (0.42); 0.63 -0.42 (0.40); 0.31 
Relative change in Hb on day 10     
G6PD normal % change g/dL (sd) -0.51 (10.76) 1.49 (11.77) -0.49 (11.76) 1.37 (10.64) 
G6PD heterozygous  % change g/dL (sd) -7.53 (7.26) -1.93 (12.54) 1.99 (9.01) 1.30 (12.27) 
 Comparison G6PD normal,    (se); p-value* -5.13 (2.69); 
0.059 
-1.34 (2.82); 0.64 2.69 (2.53); 0.29 0.56 (2.22); 0.80 
G6PD hemi-/homozygous % change g/dL (sd) -5.16 (13.39) 1.48 (10.11) 5.06 (11.46) -5.60 (7.13) 
 Comparison G6PD normal,    (se) p-value* -3.34 (4.76); 0.48 -3.67 (3.19); 0.25 1.80 (3.96); 0.65 -4.12 (3.64); 0.26 
All primaquine or placebo treatment was administered together with six doses of artemether-lumefantrine (AL); primaquine/placebo was given on day 2 of 
treatment, together with dose 5 of AL. Sd=standard deviation; * p-value compared to G6PD normal individuals, adjusted for baseline Hb concentration.  
 
 
